Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
epidermal growth factor receptor (EGFR)
Pharma
J&J's Rybrevant-Lazcluze tops AZ's Tagrisso on overall survival
J&J’s combo of Rybrevant and Lazcluze has racked up an overall survival win versus AZ’s Tagrisso in first-line non-small cell lung cancer.
Kevin Dunleavy
Jan 7, 2025 8:00am
Despite J&J's full nod, FDA endorses Dizal's accelerated plan
Jun 26, 2024 11:08am
J&J's Rybrevant moves into first line in lung cancer subtype
Mar 4, 2024 11:13am
AZ touts lung cancer advances for Tagrisso, ADC
Feb 20, 2024 1:09pm
AZ's Tagrisso combo shows edge, but survival data leave doubts
Sep 10, 2023 10:05pm
J&J notches Rybrevant trial win as Tagrisso showdown nears
Sep 6, 2023 11:35am
